BATON ROUGE, La., Jan. 06, 2017 -- Amedisys, Inc. (NASDAQ:AMED), one of America's leading home health and hospice care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2017.
The presentation will begin at 12:00 p.m. Pacific Time. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
Our company website address is http://www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding the Company is routinely posted on and accessible on the "Investor Relations" subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. We will also use our website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission ("SEC") disclosing the same information. In addition, we make available on the Investor Relations subpage of our website (under the link "SEC filings") free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct and the charters for the Audit, Compensation and Nominating and Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link "Corporate Governance").
Contact: Amedisys, Inc. David Castille Managing Director, Finance 225.299.3665 [email protected]


RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Apple Turns 50: From Garage Startup to AI Crossroads
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Bank of America's $72.5M Epstein Settlement: What You Need to Know
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



